Table 4 Progression free survival
From: Phase II assessment of talabostat and cisplatin in second-line stage IV melanoma
----------Time to PD or Death (days)a---------- | |
|---|---|
Median (95% CI), days | |
Overall PFS (N = 74) b | 92.0 (79.0, 126.0) |
Exploratory Analyses | |
PFS by: | |
M classification | |
M1a (n = 7) | 85.0 (40.0, 270.0) |
M1b (n = 13) | 135.0 (103.0, 205.0) |
M1c (n = 54) | 85.0 (68.0, 110.0) |
Prior chemotherapy | |
With (n = 40) | 89.0 (78.0, 143.0) |
Without (n = 34) | 97.0 (42.0, 180.0) |
Dose escalation of talabostat | |
With (n = 44) | 135.0 (89.0, 170.0) |
Without (n = 30) | 79.0 (42.0, 109.0) |
Initial cisplatin dose | |
100 mg/m2 (n = 35) | 80.0 (44.0, 103.0) |
75 mg/m2 (n = 39) | 126.0 (85.0, 169.0) |